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pneumonitis. Patients with minimum grade 2 were considered 
as RP. 
 
Results: Composite perfusion changes were associated with 
dose. Statistically significant dose-dependent reduction in 
regional perfusion was observed at 3, 6 and 12 months FU. 
Comparison of dose-response curves based on their slopes 
showed a dose-dependent reduction in perfusion at all time 
intervals (R2=0.8-0.9) except 1 month (R2=0.4). Relative 
perfusion loss per dose bin was 4% at 1 month, 14% at 3 
months, 13% at 6 months and 21% at 12 months FU (Figure 1).  
 
The dose-response relations varied between patients with or 
without RP. In patients who developed RP, perfusion 
reduction was larger in 20-40 Gy dose bin at 3 months FU 
(p=0.04), and in >60 Gy dose bin at 6 months (p=0.03), 
compared to those without the complication. Low dose 
regions, on the contrary, revealed larger perfusion increase 
at 12 months FU in the patients with RP (p=0.002). 
 
Conclusion: Progressive dose dependent perfusion loss was 
seen on SPECT up to 12 months following IMRT. Patients with 
radiation pneumonitis demonstrate a larger perfusion loss in 
the high dose regions, as well as relatively larger perfusion 
increase in regions receiving low dose, possibly due to 
function being shunted to these areas. 
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Purpose or Objective: There are several potentially 
radioresistant targets for dose escalation in dose-painting 
apporoach. Among them tumor hypoxia is a very attractive 
target. However, 2-3 times higher radiation dose is required 
to overcome hypoxia-mediated radioresistance in tumors, 
which is clinically difficult to achieve due to normal tissues 
constraints. Therefore, we propose a novel treatment 
approach to combine 1) targeting hypoxic tumor cells with a 
hypoxia-activated prodrug (HAP) TH302 and 2) at the same 
time use inverse radiation dose-painting strategy to boost 
tumor subvolumes with no/low drug uptake. We tested this 
approach in a rat rhabdomyosarcoma model using 18F-HX4 
hypoxia tracer, which is a surrogate of TH302 accumulation in 
a tumor. 
 
Material and Methods: A clinical PET/CT scanner was used to 
evaluate 18F-HX4 uptake 3 hrs post injection. Low or high 
drug uptake volume (LDUV or HDUV) was defined as 40% of 
the GTV with the highest or the lowest 18F-HX4 uptake, i.e. 
TH302 accumulation. Within 24 hrs after PET/CT animals 
(n=9) received either a single dose radiotherapy (RT) 
uniformly or a dose-painted non-uniform irradiation with 50% 
higher dose to LDUV or to HDUV. Mean dose in uniform RT 
was 18.5 Gy similarly to the mean dose in DUV. Mean dose to 
the GTV in the non-uniform RT scenario was 14.9 Gy. 
Treatment plans were created using Eclipse treatment 
planning system. Animals were irradiated on a TrueBeam 
High Definition 120 Leaf MLC linac. Tumor response was 
quantified as time required to reach 3-times starting tumor 
volume (TGTV3). 
 
Results: Non-uniform RT with radiation boost to tumor 
subvolumes with low TH302 uptake (LDUV) was much more 
effective than the same dose escalation to subvolumes with 
high drug uptake (Fig. 1). Noteworthy, dose escalation to 
LDUV was as effective as uniform RT with 3.6 Gy higher mean 
dose to GTV. 
 
Fig. 1.Time to reach 3-times starting tumor volume (TGTV3) 
after uniform RT or non-uniform RT with dose escalation to 
tumor volume with high drug uptake (HDUV) or low drug 
uptake (LDUV). Mean dose (Dm) to GTV is indicated. 
 
Conclusion: The results of this pilot study support targeted 
dose escalation in non-hypoxic tumor subvolumes with 
no/low accumulation of hypoxia-activated prodrugs, which 
requires further confirmation. This strategy appears to be as 
effective as a uniform dose escalation of the entire GTV but 
with greater capacity to spare normal tissues. It is expected 
that this approach of inverse dose-painting can be combined 
with other imageable cytotoxic drugs, which warrants further 
investigations. 
 





How to bring QUANTEC into the 21st century? 
C. Fiorino




The implicit concept behind the title of this lecture concerns 
the role of “quantitative” data-driven approaches in 
assessing dose-volume effects in normal tissues in the era of 
“high-tech” radiotherapy and integration of “omics”. The 
continuously growing literature regarding dose-volume 
relationships indirectly reflects the need of improving and 
refining our knowledge in this field [1]. This seems to be 
particularly urgent in a number of clinically relevant 
situations such as, for instance, heart, bowel and bladder. 
However, the impact of the above mentioned elements 
(“high-tech & “omics”) on the research issues of this field is 
increasingly relevant and claims for the development of new 
research lines and methods that will shortly be overviewed in 
the lecture.  
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The occurrence of radiation-induced toxicity is a very 
complex process that is always modulated by the individual 
[2]; if two patients receive the “same dose distribution” they 
will likely have different reactions and possibly one will 
experience toxicity while the other not. The availability of 
individual information potentially characterizing the patient 
response, including the “omics” information, is highly 
valuable, especially in the “high-tech” era of image-
guided/adaptive IMRT in which organs are more efficiently 
spared: the better sparing reduces the incidence and severity 
of toxicities and, at the same time, enhances the impact of 
individual sensitivity factors. This point reinforces the need 
to create large data bases including individually assessed 
clinical, biological and genetic information, in addition to the 
individual dose distribution. As a consequence, the approach 
of quantitatively modelling dose-volume relationships is 
increasingly becoming “phenomenological” [3]: robust 
methods for (dosimetric and non-dosimetric) variable 
selection able to condense the information in “reliable”, 
friendly to use, predictive models is a major field of 
research: the adaptation of statistical methods for data-
mining and to avoid over-fitting is a pivotal point of the 
story.  
Although the potentials of large data bases and of data 
sharing platforms on toxicity modelling are clear [4], we 
should not forget that the creation of large data-bases is not 
the “aim” but is a (powerful) “tool”. The outcome of the 
process in terms of robustness and reliability of the models 
will not only depend on the “numbers” (a highly important 
component) but also (and maybe more importantly) on the 
“quality” of data. Differently from the “easy” score of the 
success of a therapy (survival, tumour control), toxicity is a 
much more complex issue that deserves specific attention 
and the careful collection of patient-reported and/or 
physician-reported information, often for years. Well 
assessed prospective observational studies focused on 
specific toxicities seem to be the best choice; secondary 
analyses of high-quality data coming from controlled trials 
are also very important although they may be limited in some 
cases by too homogenous protocols restricting the spread of 
the delivered dose distributions.  
At the end of the circle, the external validation of integrated 
dose-volume models is clearly a crucial component of the 
next year’s research [3]: testing the generalizability of dose-
volume models will be a major end-points. In addition, robust 
results from phenomenological models are expected to feed 
up mechanistic approaches in a sort of mutual synergy that 
can further corroborate our knowledge: these two 
components (mechanistic and phenomenological) will likely 
cooperate much more in the next future. Relevant 
developments are expected to impact the quantitative 
modelling of normal tissue effects also from the side of the 
dosimetry data. The robust, organ-planning-DVH approach to 
quantitatively describe the relationship between 
dose/volume and toxicities should be overcome/refined in 
many relevant situations by directly looking to the 3D dose 
distribution, integrating the spatial information lost when 
using “classical” surrogates like DVH/EUD. Relevant examples 
are: the direct measurement of dose-map dissimilarities 
between patients [5], the quantification of local (and organ) 
effects by imaging biomarkers [6], the interplay between the 
dose received by different organs, the impact of anatomy 
changes during therapy and their incorporation into normal 
tissue predictive models.  
Quantitative modelling of normal tissue effects is lively 
present in current century and seems to have a brilliant 
future in contributing to rapidly improve the way we treat 
our patients with the promise to continuously reduce 
toxicity.  
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Drawing on experience as a practicing GP with a special 
interest in communication skills and shared decision making, 
the work of The Health Foundation funded MAGIC (Making 
Good decisions in Collaboration) programme and most 
recently on a collaboration with a Danish Oncology Hospital, 
Dr Dave Tomson will explore recent developments in Shared 
Decision Making (SDM). Using experience and expertise from 
the delegates we will 
a) check out attitudes and beliefs about the need and 
rationale for putting SDM centre stage in patient interactions,  
b) look at a useful model of SDM both for personal clinical 
practice and for teaching other clinicians,  
c) explore some of the key skills needed and the key 
challenges in doing better SDM with a particular focus on 
oncology – the constant changing nature of the evidence 
base, individualised care in a guideline driven world, dealing 
with personal bias, unwarranted versus warranted variation 
in practice, the tyranny of time.  
d) share some ideas about possible solutions to these 
challenges and think about some of the steps needed to both 
develop personal practice and implement programmes of 
development within departments and across hospital systems 
 
Teaching Lecture: The study of therapy resistance in 
genetically engineered mouse models for BRCA1-mutated 
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Although various effective anti-cancer treatments have 
become available over the last decades, therapy resistance 
remains the major cause of death of cancer patients. Striking 
examples are patients with tumors that are defective in DNA 
repair by homologous recombination (HR). Despite initial 
responses to cancer therapy, resistance of primary or 
disseminated tumors eventually emerges, which minimizes 
therapeutic options and greatly reduces survival. The 
molecular mechanisms underlying this therapy escape are 
often poorly understood.  
A clinically relevant mechanism for the defect in HR is a lack 
of function of BRCA1. This defect impairs error-free repair of 
DNA double-strand breaks (DSB) – a feature that can be 
exploited by the treatment with DSB-inducing agents. Using 
the K14cre,Brca1F/F,p53F/F (KB1P) genetically engineered 
mouse model for BRCA1-mutated breast cancer, we have 
shown the success of this strategy. Tumors are highly 
sensitive to DNA cross-linking agents, or to the inhibition of 
topoisomerase I/II and poly (ADP-ribose) polymerase (PARP) 
(reviewed by Rottenberg & Borst, 2012). Despite this 
sensitivity, tumors are not eradicated and eventually drug-
refractory tumors emerge. In several of the resistant tumors 
we found that the HR defect can be partially rescued by 
down-regulation or knock-out of additional repair factors, 
such as 53BP1 (Jaspers et al. 2013) or REV7 (Xu et al. 2015).  
Based on these observations we set out to investigate 
whether this type of HR restoration can also explain 
radiotherapy resistance. For this purpose, we treated mice 
carrying KB1P tumors with high-precision radiotherapy. We 
